Literature DB >> 7655782

Paclitaxel-induced cutaneous toxicity.

T Berghmans1, J Klastersky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7655782     DOI： 10.1007/bf00368892

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  6 in total

1.  Taxol-induced soft-tissue injury secondary to extravasation: characterization by histopathology and clinical course.

Authors:  J A Ajani; L G Dodd; K Daugherty; D Warkentin; D H Ilson
Journal:  J Natl Cancer Inst       Date:  1994-01-05       Impact factor: 13.506

2.  Nursing considerations in paclitaxel (Taxol) administration.

Authors:  B G Lubejko; S E Sartorius
Journal:  Semin Oncol       Date:  1993-08       Impact factor: 4.929

Review 3.  Clinical toxicities encountered with paclitaxel (Taxol).

Authors:  E K Rowinsky; E A Eisenhauer; V Chaudhry; S G Arbuck; R C Donehower
Journal:  Semin Oncol       Date:  1993-08       Impact factor: 4.929

Review 4.  The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).

Authors:  R Pazdur; A P Kudelka; J J Kavanagh; P R Cohen; M N Raber
Journal:  Cancer Treat Rev       Date:  1993-10       Impact factor: 12.111

5.  Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting.

Authors:  E K Rowinsky; V Chaudhry; A A Forastiere; S E Sartorius; D S Ettinger; L B Grochow; B G Lubejko; D R Cornblath; R C Donehower
Journal:  J Clin Oncol       Date:  1993-10       Impact factor: 44.544

Review 6.  Administration of chemotherapeutic agents. Techniques and controversies.

Authors:  J H Raaf
Journal:  Support Care Cancer       Date:  1994-11       Impact factor: 3.603
  6 in total
  1 in total

Review 1.  A review of clinical experience with paclitaxel extravasations.

Authors:  Brad L Stanford; Fred Hardwicke
Journal:  Support Care Cancer       Date:  2003-03-27       Impact factor: 3.603
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.